儿童期起病结节性多动脉炎与DADA2的系统综述
DADA2患者起病年龄更小,父母近亲婚配、网状青斑、神经系统受累(尤其卒中)、淋巴细胞减少和低丙种球蛋白血症更常见,而血小板增多和脂膜炎较少见。结论提示对PAN样表型患儿应警惕DADA2,抗TNF治疗是DADA2血管炎的主要选择,严重PAN在PVAS确认缓解后可将环磷酰胺转换为吗替麦考酚酯。
要点
- 儿童PAN样表型若起病年龄小、有父母近亲婚配、卒中、淋巴细胞减少且无血小板增多,需考虑DADA2。
- DADA2患者神经系统、胃肠道和心脏受累更常见,PAN患者全身症状和睾丸受累更常见。
- DADA2的主要治疗为抗TNF;严重PAN诱导用糖皮质激素联合环磷酰胺或吗替麦考酚酯,PVAS确认缓解后环磷酰胺可转换为吗替麦考酚酯。
核心结论
- 儿童PAN样表型中,起病年龄小、父母近亲婚配、卒中、淋巴细胞减少及活动期无血小板增多提示DADA2可能。
- 血管炎性DADA2适用抗TNF治疗;严重PAN在PVAS确认缓解后可将环磷酰胺转换为吗替麦考酚酯。
研究设计与样本
- 系统文献检索纳入28篇描述613例儿童PAN和26篇描述207例儿童DADA2的文章。
主要发现
- DADA2患者起病年龄更小,父母近亲婚配、网状青斑、神经系统受累(尤其卒中)、淋巴细胞减少和低丙种球蛋白血症更常见。
- DADA2患者血小板增多和脂膜炎较少见。
- 文献汇总显示DADA2患者神经系统、胃肠道和心脏受累更频繁,PAN患者全身症状和睾丸受累更常见。
关键数值与推荐
- DADA2主要治疗为抗TNF。
- 所有系统性PAN患者诱导治疗均接受糖皮质激素,其中11例联合环磷酰胺、3例联合吗替麦考酚酯。
- 9例患者在PVAS确认缓解后由环磷酰胺转换为吗替麦考酚酯。
临床怎么用
- 对儿童PAN样表型应评估DADA2相关线索:起病年龄小、父母近亲婚配、卒中、淋巴细胞减少及活动期无血小板增多。
- 血管炎性DADA2优先考虑抗TNF治疗。
- 严重PAN诱导缓解后,经PVAS确认缓解可考虑将环磷酰胺转换为吗替麦考酚酯。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diagnosis of childhood polyarteritis nodosa (PAN) has become challenging after the definition of deficiency of adenosine deaminase 2 (DADA2). We aimed to define the differential features of pediatric PAN and DADA2 patients in our center and in the literature. METHODS: The charts of pediatric PAN and DADA2 patients followed at the Pediatric Rheumatology Unit of Hacettepe University between 2010-2020 were analyzed. A systematic literature review was conducted for articles regarding pediatric PAN or DADA2. RESULTS: Thirty-four pediatric PAN and 18 pediatric DADA2 patients were included. The age at onset was younger, parental consanguinity, livedo reticularis, neurologic involvement (especially strokes), lymphopenia, and hypogammaglobulinemia were more frequent, while thrombocytosis and panniculitis were less frequent in DADA2 patients. The primary treatment was anti-tumor necrosis factor (anti-TNF) in DADA2. For induction treatment, all systemic PAN patients received corticosteroids, and cyclophosphamide (n=11) or mycophenolate mofetil (MMF) (n = 3). Cyclophosphamide was replaced with MMF in nine once remission was confirmed with PVAS. In the literature, 28 articles describing 613 pediatric PAN patients and 26 articles describing 207 pediatric DADA2 patients were identified. Neurologic, gastrointestinal, and cardiac involvements were more frequent in DADA2, while constitutional symptoms and testis involvement were more common in PAN. CONCLUSION: In a child with PAN-like phenotype, DADA2 should be considered in the presence of young age at disease onset, parental consanguinity, strokes, lymphopenia, and lack of thrombocytosis during active disease. Anti-TNF treatment is indicated for vasculitic DADA2. Cyclophosphamide could be switched to MMF when remission is confirmed with PVAS in severe PAN.
引用
- Kasap Cuceoglu M, Sener S, Batu ED, et al. Systematic review of childhood-onset polyarteritis nodosa and DADA2. Semin Arthritis Rheum. 2021. PMID: 33901990. doi:10.1016/j.semarthrit.2021.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。